✦ LIBER ✦

207 speaker UPDATE OF THREE MAJOR PHASE III RANDOMIZED TRIALS FROM THE EORTC BREAST AND RADIOTHERAPY GROUP.

✍ Scribed by H. Bartelink; S. Litière; S. Collette; L. Collette; J. Bogaerts; E. Rutgers; N. Bijker; M. Donker; E. van Werkhoven

Book ID: 119518948
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 45 KB
Volume: 99
Category: Article
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(11)70329-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

2–45 Breast-Conserving Treatment With or

2–45 Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

✍ Wong, J.S. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 70 KB

Breast-Conserving Treatment With or With

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial

✍ Donker, M.; Litiere, S.; Werutsky, G.; Julien, J.-P.; Fentiman, I. S.; Agresti, 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 163 KB

127Immediate hormonal therapy improves l

127Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer. Results of a randomized phase III clinical trial of the eortc radiotherapy and genito-urinary tract cancer cooperative groups

✍ Bolla, M.; Gonzelez, D.; Warde, P.; Dubois, J.B.; Mirimanoff, R.; Storme, G.; Be 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 105 KB

First results of a randomized phase III

First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group

✍ R Paridaens; P Therasse; L Dirix; L Beex; M.J Piccart; D Cameron; T Cufer; K Roo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB

P.39 Docetaxel plus epirubicin (DE) vs d

P.39 Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Karampeazis, A.; Ardavanis, A.; Souglakos, I.; Kalbakis, K.; Varda 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Paclitaxel plus cisplatin is as effectiv

Paclitaxel plus cisplatin is as effective as regimens containing gemcitabine in people with advanced non-small cell lung cancer: Abstracted from: Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003;21:3909–17.

✍ Sarah Danson 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 163 KB